Daxor

Daxor EBITDA per Share

The EBITDA per Share of Daxor (DXR) as of Oct 16, 2026 is 1.82 USD. In the previous year, EBITDA per Share was 0.13 USD — a change of 1,341.54% (higher).

EBITDA per Share

1.82USD

YoY

1,341.54%

Last updated:

EBITDA per Share of Daxor is 2025 1.82 USD. EBITDA per Share of Daxor was 2024 0.13 USD. It decreases by 1,341.54% higher compared to the previous year.

The Daxor EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.29 USD
Jan 1, 2019
-0.12 USD
Jan 1, 2020
-0.21 USD
Jan 1, 2021
0.59 USD
Jan 1, 2022
0.61 USD
Jan 1, 2023
0.07 USD
Jan 1, 2024
0.13 USD
Jan 1, 2025
1.82 USD
The Daxor EBITDA per Share history
YEAREBITDA per ShareYoY
1.82USD+1,341.54%
0.13USD+76.89%
0.07USD-88.36%
0.61USD+4.09%
0.59USD-374.01%
-0.21USD+81.18%
-0.12USD-59.56%
-0.29USD-4.22%
-0.31USD-179.13%
0.39USD-118.88%
-2.05USD+81.14%
-1.13USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Daxor Stock analysis

What does Daxor do? Daxor Corp, listed on the ticker DXR with ISIN US2394671034, is a health care company based in New York City, United States. The company went public on July 25, 1983. Daxor Corp develops and manufactures the BVA-100 blood volume analyzer, a diagnostic instrument cleared by the U.S. Food and Drug Administration (FDA). This device measures human blood volume and provides objective quantification of blood volume status and composition relative to patient-specific norms. The company reports that over 65,000 tests have been conducted at hospital centers across the United States. These tests are associated with improvements in hospital performance metrics for various surgical and medical conditions, including reductions in mortality and readmissions for heart failure and critical care patients. Daxor Corp is engaged in advancing healthcare through blood volume analysis, focusing on optimal fluid management. The company is conducting ongoing clinical trials related to heart failure treatment, supported by the National Institutes of Health (NIH), and is also under contract to develop additional analyzers. The company's website is https://www.daxor.com/. Daxor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Daxor stock

EBITDA per Share of Daxor is 1.82 USD in 2025.

EBITDA per Share of Daxor changed from 0.13 USD to 1.82 USD, representing a 1,341.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Daxor since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Daxor

All Key Metrics — Daxor